Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases
IBDs (inflammatory bowel diseases) are lifelong manifestations that significantly impair the quality of life of those who suffer from them. Although many therapies are now available, including immunomodulatory drugs such as Infliximab which have efficacy in IBD, not all patients respond and some patients generate autoantibodies against these drugs. Hence the search for novel treatments is ongoing. HDACs (histone deacetylases) are responsible for condensation of chromatin in the nucleus of cells and inhibition of gene transcription and are often dysregulated during cancer. HDAC inhibitors allow normal gene transcription to be restored and provide attractive therapeutic options, as they have been shown to be anti-inflammatory and anti-proliferative in cancer. Indeed, two HDAC inhibitors have been recently approved for the treatment of cutaneous T-cell lymphoma in the U.S.A. Recent research using animal models has shown that HDAC inhibitors may have a beneficial effect in colitis by boosting levels of Foxp3+ (forkhead box P3+) T-regulatory cells that dampen inflammation. In the present paper, we outline the background to IBD, HDACs and their inhibitors as well as discussing their current use in models of IBD.
crohn's disease, forkhead box p3 (foxp3), histone deacetylase, inflammatory bowel disease, ulcerative colitis
1092-1095
Edwards, Alexander J.P.
0dda43aa-b92f-4449-86f1-6d69a0c41f3a
Pender, Sylvia L.F.
62528b03-ec42-41bb-80fe-48454c2c5242
1 August 2011
Edwards, Alexander J.P.
0dda43aa-b92f-4449-86f1-6d69a0c41f3a
Pender, Sylvia L.F.
62528b03-ec42-41bb-80fe-48454c2c5242
Edwards, Alexander J.P. and Pender, Sylvia L.F.
(2011)
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
Biochemical Society Transactions, 39 (4), .
(PMID:21787354)
Abstract
IBDs (inflammatory bowel diseases) are lifelong manifestations that significantly impair the quality of life of those who suffer from them. Although many therapies are now available, including immunomodulatory drugs such as Infliximab which have efficacy in IBD, not all patients respond and some patients generate autoantibodies against these drugs. Hence the search for novel treatments is ongoing. HDACs (histone deacetylases) are responsible for condensation of chromatin in the nucleus of cells and inhibition of gene transcription and are often dysregulated during cancer. HDAC inhibitors allow normal gene transcription to be restored and provide attractive therapeutic options, as they have been shown to be anti-inflammatory and anti-proliferative in cancer. Indeed, two HDAC inhibitors have been recently approved for the treatment of cutaneous T-cell lymphoma in the U.S.A. Recent research using animal models has shown that HDAC inhibitors may have a beneficial effect in colitis by boosting levels of Foxp3+ (forkhead box P3+) T-regulatory cells that dampen inflammation. In the present paper, we outline the background to IBD, HDACs and their inhibitors as well as discussing their current use in models of IBD.
This record has no associated files available for download.
More information
Published date: 1 August 2011
Keywords:
crohn's disease, forkhead box p3 (foxp3), histone deacetylase, inflammatory bowel disease, ulcerative colitis
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 195603
URI: http://eprints.soton.ac.uk/id/eprint/195603
ISSN: 0300-5127
PURE UUID: 218bca15-5721-4f65-b93c-3de2f123bfc5
Catalogue record
Date deposited: 23 Aug 2011 14:11
Last modified: 23 Jul 2022 01:48
Export record
Contributors
Author:
Alexander J.P. Edwards
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics